| Title |
Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2013
|
| DOI | 10.2147/tcrm.s41131 |
| Pubmed ID | |
| Authors |
Francesco Blasi, Paolo Tarsia, Marco Mantero, Letizia C Morlacchi, Federico Piffer |
| Abstract |
The aim of this open-label, randomized, parallel-group pilot study was to evaluate the efficacy of cefditoren pivoxil and levofloxacin in terms of speed of reduction in inflammatory parameters, clinical recovery, and microbiological eradication. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Lecturer | 3 | 11% |
| Student > Postgraduate | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Researcher | 2 | 7% |
| Student > Doctoral Student | 1 | 4% |
| Other | 5 | 19% |
| Unknown | 12 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 26% |
| Social Sciences | 2 | 7% |
| Immunology and Microbiology | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Computer Science | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 14 | 52% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,007
of 1,308 outputs
Outputs of similar age
#222,950
of 292,111 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 8 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,111 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.